![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is de... Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital. Show more
U.S. index futures are virtually flat in pre-market trading this Wednesday, with Wall Street awaiting April’s consumer price index data. At 7:18 AM, Dow Jones futures (DOWI:DJI) were up 3...
CAMBRIDGE, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc.Β (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing...
CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc.Β (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel...
CAMBRIDGE, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc.Β (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing...
Period β | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.0399 | -2.91240875912 | 1.37 | 1.38 | 1.25 | 253377 | 1.30489293 | CS |
4 | -0.1299 | -8.89726027397 | 1.46 | 1.5001 | 1.25 | 189306 | 1.38026323 | CS |
12 | -0.3699 | -21.7588235294 | 1.7 | 1.81 | 1.25 | 193187 | 1.52281391 | CS |
26 | 0.0301 | 2.31538461538 | 1.3 | 1.89 | 1.25 | 255828 | 1.58375024 | CS |
52 | -0.1899 | -12.4934210526 | 1.52 | 1.89 | 0.99 | 256844 | 1.47138271 | CS |
156 | -13.2999 | -90.9084073821 | 14.63 | 19.87 | 0.6801 | 965076 | 2.26468563 | CS |
260 | -12.1299 | -90.118127786 | 13.46 | 23.639 | 0.6801 | 644745 | 3.52469254 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions